Cleveland、OHにおける卵巣がんの臨床試験
Clevelandとその周辺地域（約30マイル以内）の拠点で、卵巣がんに関する30件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
The Vanguard Study: Testing a New Way to Screen for Cancer
被験者募集中健康なボランティア歓迎
- Louis Stokes Cleveland VA Medical Center, Cleveland
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
被験者募集中第2相
- Case Western Reserve University, Cleveland
- UHHS-Chagrin Highlands Medical Center, Beachwood · 10マイル先
- UH Seidman Cancer Center at Lake Health Mentor Campus, Mentor · 22マイル先
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
被験者募集中第1相
- University Hospitals Cleveland Medical Center, Cleveland
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
被験者募集中第1/2相
- The Cleveland Clinic Taussig Cancer Center, Cleveland
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
被験者募集中第2相
- Cleveland Clinic - Oncology Department, Cleveland
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
被験者募集中第2相
- University Hospitals Cleveland Medical Center /ID# 279601, Cleveland
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer
被験者募集中第3相
- Research Site, Cleveland
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
被験者募集中観察研究
- Cleveland Clinic, Cleveland
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
被験者募集中第2相
- Metrohealth Medical Center - Cleveland /ID# 276664, Cleveland
- Cleveland Clinic - Cleveland /ID# 276133, Cleveland
- Cleveland Clinic - Cleveland /ID# 278273, Cleveland
- 他1件
Study of AVZO-021 in Patients With Advanced Solid Tumors
被験者募集中第1/2相
- Avenzo Therapeutics Recruiting Site, Cleveland
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
被験者募集中第3相
- University Hospitals Cleveland Medical Center, Cleveland
- Fairview Hospital, Cleveland
- Cleveland Clinic, Cleveland
- 他1件
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
被験者募集中第1/2相
- UH Cleveland Medical Center, Cleveland
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
被験者募集中第3相
- Cleveland Clinic Foundation, Cleveland
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
被験者募集中観察研究
- Cleveland Clinic, Cleveland
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
被験者募集中第3相
- Cleveland Clinic, Cleveland
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
被験者募集中第3相
- Cleveland Clinic, Cleveland
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
被験者募集中第1相
- Cleveland Clinic Taussig Cancer Institute, Cleveland
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
被験者募集中
- Case Western Reserve University, Cleveland
- MetroHealth Medical Center, Cleveland
- Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland
- 他4件
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
被験者募集中第3相
- Case Western Reserve University, Cleveland
- Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland
- Cleveland Clinic Foundation, Cleveland
- 他3件
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
被験者募集中第1相
- University Hospital - Cleveland Medical Center, Cleveland
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
被験者募集中第3相
- The Cleveland Clinic Foundation, Cleveland
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- UH Cleveland Medical Center, Cleveland
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
被験者募集中第1/2相
- Research site, Cleveland
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
被験者募集中第3相
- University Hospitals Cleveland Medical Center, Cleveland
- Cleveland Clinic, Cleveland
- UH Minoff Health Center at Chagrin Highlands, Orange · 12マイル先
- 他1件
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
被験者募集中観察研究
- University Hospitals Seidman Cancer Center, Cleveland
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
被験者募集中第1相
- Cleveland Clinic, Cleveland
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
被験者募集中観察研究健康なボランティア歓迎
- Cleveland Clinic, Cleveland
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Mayfield Heights · 12マイル先
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
被験者募集中第1相
- Exelixis Clinical Site #7, Cleveland
Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer
被験者募集中第2相
- University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland
他の都市における卵巣がんの試験
- Houston, TX89件の研究
- New York City, NY69件の研究
- Boston, MA61件の研究
- Los Angeles, CA50件の研究
- Nashville, TN49件の研究
- Arlington, VA46件の研究
- Philadelphia, PA44件の研究
- Columbus, OH39件の研究
- St. Louis, MO38件の研究
- Chicago, IL36件の研究
- San Antonio, TX31件の研究
- Pittsburgh, PA30件の研究
Clevelandにおける他の研究
- 非小細胞肺癌43件の研究
- がん（全種類）36件の研究
- 乳がん35件の研究
- 前立腺がん34件の研究
- 心不全33件の研究
- 転移性癌30件の研究
- 肺がん26件の研究
- 大腸癌24件の研究
- 心血管疾患22件の研究
- 子宮内膜がん20件の研究
- 急性骨髄性白血病20件の研究
- クローン病19件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。